Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Joseph R. DiPersio is active.

Publication


Featured researches published by Joseph R. DiPersio.


Antimicrobial Agents and Chemotherapy | 2008

First Report of cfr-Mediated Resistance to Linezolid in Human Staphylococcal Clinical Isolates Recovered in the United States

Rodrigo E. Mendes; Lalitagauri M. Deshpande; Mariana Castanheira; Joseph R. DiPersio; Michael A. Saubolle; Ronald N. Jones

ABSTRACT Linezolid resistance has dominantly been mediated by mutations in 23S rRNA or ribosomal protein L4 genes. Recently, cfr has demonstrated the ability to produce a phenotype of resistance to not only oxazolidinones, but also other antimicrobial classes (phenicols, lincosamides, pleuromutilins, and streptogramin A). We describe the first detection of cfr-mediated linezolid resistance in Staphylococcus aureus and Staphylococcus epidermidis recovered from human infection cases monitored during the 2007 LEADER Program.


Clinical Infectious Diseases | 2003

Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.

Kevin B. Anderson; James S. Tan; Thomas M. File; Joseph R. DiPersio; Barbara M. Willey; Donald E. Low

We describe 4 patients infected with levofloxacin-resistant pneumococci after therapy for community-acquired pneumonia (CAP). The 4 patients had 15 episodes of CAP; Streptococcus pneumoniae was isolated from blood or sputum samples obtained during 14 of the episodes. The underlying medical condition was Bruton agammaglobulinemia in 3 patients and chronic lymphoid leukemia in the other. The initial episode of CAP in each patient was due to a levofloxacin-susceptible strain. One of 4 reinfections and 5 of 6 relapses were due to levofloxacin-resistant strains. All of these strains had amino acid substitutions in the quinolone-resistance-determining region of the genes parC and gyrA. The time between episodes of pneumonia varied from 1 to 4 months. In immunocompromised patients with suspected or proven pneumococcal infection, it may be prudent not to use fluoroquinolone monotherapy empirically when the patient has a history of fluoroquinolone therapy in at least the past 4 months.


Antimicrobial Agents and Chemotherapy | 2010

Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species

Guillermo Garcia-Effron; Daniel Joseph Chua; Jon Rupert Tomada; Joseph R. DiPersio; David S. Perlin; Mahmoud A. Ghannoum; Hector Bonilla

ABSTRACT We studied three clinical isolates of Candida spp. (one C. tropicalis isolate and two C. glabrata isolates) from patients with invasive candidiasis. The first isolate emerged during echinocandin treatment, while the others emerged after the same treatment. These strains harbored an amino acid substitution in Fksp never linked before with reduced echinocandin susceptibility in C. tropicalis or in C. glabrata. The molecular mechanism of reduced susceptibility was confirmed using a 1,3-β-d-glucan synthase inhibition assay.


Journal of Clinical Microbiology | 2009

First Descriptions of blaKPC in Raoultella spp. (R. planticola and R. ornithinolytica): Report from the SENTRY Antimicrobial Surveillance Program

Mariana Castanheira; Lalitagauri M. Deshpande; Joseph R. DiPersio; Julia Kang; Melvin P. Weinstein; Ronald N. Jones

ABSTRACT Two strains of Raoultella planticola and one of Raoultella ornithinolytica showing carbapenem resistance were recovered from patients hospitalized in New Jersey and Ohio. All patients had received previous antimicrobial treatment, including carbapenems. These strains harbored blaKPC-2 and blaKPC-3. Carbapenemase genes were embedded in isoforms of Tn4401 and were plasmidic and chromosomal in location.


Antimicrobial Agents and Chemotherapy | 2010

Susceptibility of Gram-Negative Pathogens Isolated from Patients with Complicated Intra-Abdominal Infections in the United States, 2007-2008: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART)

Daryl J. Hoban; S. Bouchillon; Robert E. Badal; Vincent J. LaBombardi; Joseph R. DiPersio

ABSTRACT During 2007-2008, 1,036 Gram-negative bacilli were isolated from patients with complicated intra-abdominal infections in the United States. Against members of the family Enterobacteriaceae, the most active agents in vitro were ertapenem, imipenem, and amikacin, while the least active agent was ampicillin-sulbactam. Ertapenem and imipenem were active against all extended-spectrum-beta-lactamase (ESBL)-positive Escherichia coli. Antimicrobial resistance in Gram-negative bacilli isolated from patients with complicated intra-abdominal infections in the United States continues to increase.


Diagnostic Microbiology and Infectious Disease | 1998

Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998).

Joseph R. DiPersio; Ronald N. Jones; Timothy Barrett; Gary V. Doern; Michael A. Pfaller

Fluoroquinolone resistance in Moraxella catarrhalis isolates has been quite rare. This report presents a case history of a 22-year-old man with compromised immune status and severe pneumonia caused by M. catarrhalis. The organism was markedly resistant (MICs, 1.5- > 32 micrograms/mL) to several marketed fluoroquinolones including the agent (levofloxacin) used for concurrent and prior therapy. The emergence of this problematic strain seems related to chronic exposure of the patient to compounds in the class and poor patient compliance to prescribed medications. The strain was not clonally related to other M. catarrhalis strains isolated in the same hospital during early 1998. This second documented case of a fluoroquinolone-resistant M. catarrhalis clinical isolate presents a warning that resistances can emerge in at-risk patients, and that surveillance systems (SENTRY) will be necessary to monitor for unusual organisms and spread of resistance phenotypes among commonly isolated respiratory tract pathogens.


Diagnostic Microbiology and Infectious Disease | 2011

Identification and characterization of plasmid-borne erm(T) macrolide resistance in group B and group A Streptococcus

Linda P. DiPersio; Joseph R. DiPersio; Jacqueline A. Beach; Andrew M. Loudon; Ashley M. Fuchs

One hundred and seven group B Streptococcus (GBS) isolates and 344 group A Streptococcus (GAS) isolates were collected between 2005 and 2009 from 2 area hospitals and studied for resistance to erythromycin (ERY) and clindamycin (CLI) and the presence of the erm(T) macrolide resistance gene. The erm(T) gene was found in 5 (8%) of 61 erythromycin nonsusceptible GBS isolates and in 22 (55%) of 40 erythromycin nonsusceptible GAS isolates. The erm(T) gene in all 27 GBS/GAS erm(T) gene-positive isolates was located on a plasmid. Three erm(T) gene-positive plasmids were DNA sequenced. Two plasmids (1 each from GBS and GAS isolates) were both 4967 bp in size, contained the erm(T) gene, and differed by only 2 base pairs, suggesting interspecies horizontal transfer of the erm(T) gene containing plasmid. The third (GBS) plasmid was 6825 bp in size and contained GBSi1, a group II bacterial intron, as well as the erm(T) gene. Pulsed-field gel electrophoresis of all 27 erm(T) gene containing isolates and a selection of erm(T) gene-negative isolates indicated possible clonal expansion among erm(T) gene containing GAS isolates, but not among the 5 erm(T) gene-positive GBS isolates.


Antimicrobial Agents and Chemotherapy | 2008

Prevalence of the erm(T) Gene in Clinical Isolates of Erythromycin-Resistant Group D Streptococcus and Enterococcus

Linda P. DiPersio; Joseph R. DiPersio; Kevin C. Frey; Jacqueline A. Beach

ABSTRACT Among 48 erythromycin-resistant group D streptococci (GDS), 36 had the erm(T) resistance gene. erm(T) was also found in 4 of 31 erythromycin-resistant Enterococcus faecium isolates. This is the first report of the erm(T) gene in U.S. GDS isolates and the first report of the erm(T) gene in enterococci.


Journal of Clinical Microbiology | 2013

Evaluation of the BinaxNOW Staphylococcus aureus Test for Rapid Identification of Gram-Positive Cocci from VersaTREK Blood Culture Bottles

Neelam Dhiman; Tamara L. Trienski; Linda P. DiPersio; Joseph R. DiPersio

ABSTRACT The ability of the rapid BinaxNOW Staphylococcus aureus (BNSA) immunochromatographic test (Alere Scarborough, Inc., ME) to accurately differentiate S. aureus from coagulase-negative staphylococci (CoNS) and other Gram-positive cocci (GPC) directly from VersaTREK blood culture bottles was evaluated. A total of 319 positive patient blood culture bottles with GPC seen in clusters with Gram staining were tested using the BNSA test and a direct tube coagulase test (DTCT). The BNSA test was accurate for the detection and differentiation of S. aureus from CoNS and other GPC within 30 min from the time of blood culture positivity and demonstrated a test sensitivity and specificity of 95.8% and 99.6%, respectively. BNSA test results were faxed to the antimicrobial stewardship pharmacist by noon each day in order to evaluate empirical antimicrobial therapy and facilitate more rapid changes or modifications if necessary. Same-day reporting of BNSA test results in conjunction with an antimicrobial stewardship program was more impactful in improving treatment for inpatients with documented S. aureus bacteremia than in reducing empirical vancomycin use in inpatients with CoNS during the first 24 h following reporting.


Journal of Clinical Microbiology | 2010

Alternative Use for Spectra MRSA Chromogenic Agar in Detection of Methicillin-Resistant Staphylococcus aureus from Positive Blood Cultures

Jess F. Peterson; Alexander A. Dionisio; Katherine M. Riebe; Gerri S. Hall; Deborah A. Wilson; Susan Whittier; Joseph R. DiPersio; Nathan A. Ledeboer

ABSTRACT Spectra MRSA agar (Remel, Lenexa, KS), a novel chromogenic medium originally developed to detect methicillin-resistant Staphylococcus aureus (MRSA) from nasal swabs, was evaluated in this multicenter study for the detection of MRSA from positive blood cultures exhibiting Gram-positive cocci upon initial Gram staining.

Collaboration


Dive into the Joseph R. DiPersio's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

James S. Tan

Northeast Ohio Medical University

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge